A perspective on pancreatic stem/progenitor cells

Joel F Habener1

  • 1Laboratory of Molecular Endocrinology, Massachusetts General Hospital, 55 Fruit Street - WEL 320, Boston, MA 02114, USA. jhabener@partners.org

Pediatric Diabetes
|December 17, 2004
PubMed

Insights

Cell-based therapies, including stem cells, show promise for curing type 1 and type 2 diabetes by regenerating insulin-producing cells. This regenerative medicine approach offers a potential permanent solution beyond current diabetes management. Keywords: stem cells, diabetes cure, regenerative medicine, insulin-producing cells.

Area of Science:

  • Regenerative Medicine
  • Endocrinology
  • Cellular Therapy

Background:

  • Type 1 and type 2 diabetes mellitus prevalence is rising globally, leading to significant morbidity and mortality.
  • Current treatments manage diabetes but do not offer a cure, highlighting the need for novel therapeutic strategies.
  • Pancreatic islet transplantation shows potential but is limited by donor organ scarcity.

Purpose of the Study:

  • To explore the potential of cell-based therapies and regenerative medicine for achieving a permanent cure for diabetes.
  • To discuss the application of stem cells in generating functional, insulin-producing beta-cells for transplantation.
  • To consider future directions in stem cell administration for islet regeneration.

Main Methods:

  • Utilizing embryo-derived or adult tissue-derived stem cells (from pancreas, liver, bone marrow) for in vitro expansion and differentiation into islet-like clusters.
  • Transplanting these differentiated cells into streptozotocin-induced diabetic mice to assess glycemic control.
  • Investigating strategies for direct stem cell administration or stem cell stimulator use to enhance endogenous pancreatic stem cells.

Main Results:

  • Stem cells can be expanded and differentiated into insulin-producing islet-like clusters.
  • Transplanted cells have demonstrated the ability to achieve glycemic control in diabetic mouse models.
  • Potential exists for in vivo regeneration of injured islets through targeted stem cell therapy.

Conclusions:

  • Cellular medicines and regenerative medicine offer a promising pathway toward a functional cure for diabetes.
  • Stem cell-derived therapies can overcome the limitations of donor islet availability.
  • Future research may focus on systemic stem cell delivery or stimulation of endogenous repair mechanisms for diabetes treatment.